Search research articles
Contact Us
Filters
Showing results (11-20 of 26) with videos related to
Page
of 3
Sort By:
Aviation, Space, and Environmental Medicine
|
April 1, 1982
Altitude and hypoxia as phase shift inducers
I E Ashkenazi, J Ribak, D M Avgar, et al.
Biochemical and Biophysical Research Communications
|
March 27, 1997
Affinity modulation in platelet alpha 2 beta 1 following ligand binding
N Gofer-Dadosh, A Klepfish, H Schmilowitz, et al.
American Journal of Hematology
|
December 22, 1999
Advanced Hodgkin's disease in a pregnant HIV seropositive woman: favorable mother and baby outcome following combined anticancer and antiretroviral therapy
A Klepfish, A Schattner, M Shtalrid, et al.
Leukemia & Lymphoma
|
April 8, 1999
B-cell prolymphocytic leukemia: a survey of 35 patients emphasizing heterogeneity, prognostic factors and evidence for a group with an indolent course
L Shvidel, M Shtalrid, L Bassous, et al.
Leukemia
|
October 10, 1998
Epidemiology and ethnic aspects of B cell chronic lymphocytic leukemia in Israel
L Shvidel, M Shtarlid, A Klepfish, et al.
QJM : Monthly Journal of the Association of Physicians
|
July 25, 2008
Adding fresh frozen plasma to rituximab for the treatment of patients with refractory advanced CLL
A Klepfish, E A Rachmilewitz, I Kotsianidis, et al.
Platelets
|
June 24, 2006
Collagen binding induces changes in its platelet integrin receptor alpha2beta1
N Gofer-Dadosh, A Klepfish, H Schmilowitz, et al.
Leukemia & Lymphoma
|
November 9, 2001
Over-expression of the functional interleukin-11 alpha receptor in the development of B-cell chronic lymphocytic leukemia
A Tsimanis, L Shvidel, A Klepfish, et al.
Leukemia & Lymphoma
|
May 30, 2001
Primary effusion lymphoma (PEL) in HIV-negative patients--a distinct clinical entity
A Klepfish, R Sarid, M Shtalrid, et al.
Leukemia & Lymphoma
|
April 12, 2003
Successful treatment of aggressive HIV-associated non-Hodgkin's lymphoma with combination chemotherapy, biotherapy with rituximab and HAART: presentation of a therapeutic option
A Klepfish, A Schattner, L Shvidel, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 26) with videos related to
Sort By:
Page
of 3
Aviation, Space, and Environmental Medicine
|
April 1, 1982
Altitude and hypoxia as phase shift inducers
I E Ashkenazi, J Ribak, D M Avgar, et al.
Biochemical and Biophysical Research Communications
|
March 27, 1997
Affinity modulation in platelet alpha 2 beta 1 following ligand binding
N Gofer-Dadosh, A Klepfish, H Schmilowitz, et al.
American Journal of Hematology
|
December 22, 1999
Advanced Hodgkin's disease in a pregnant HIV seropositive woman: favorable mother and baby outcome following combined anticancer and antiretroviral therapy
A Klepfish, A Schattner, M Shtalrid, et al.
Leukemia & Lymphoma
|
April 8, 1999
B-cell prolymphocytic leukemia: a survey of 35 patients emphasizing heterogeneity, prognostic factors and evidence for a group with an indolent course
L Shvidel, M Shtalrid, L Bassous, et al.
Leukemia
|
October 10, 1998
Epidemiology and ethnic aspects of B cell chronic lymphocytic leukemia in Israel
L Shvidel, M Shtarlid, A Klepfish, et al.
QJM : Monthly Journal of the Association of Physicians
|
July 25, 2008
Adding fresh frozen plasma to rituximab for the treatment of patients with refractory advanced CLL
A Klepfish, E A Rachmilewitz, I Kotsianidis, et al.
Platelets
|
June 24, 2006
Collagen binding induces changes in its platelet integrin receptor alpha2beta1
N Gofer-Dadosh, A Klepfish, H Schmilowitz, et al.
Leukemia & Lymphoma
|
November 9, 2001
Over-expression of the functional interleukin-11 alpha receptor in the development of B-cell chronic lymphocytic leukemia
A Tsimanis, L Shvidel, A Klepfish, et al.
Leukemia & Lymphoma
|
May 30, 2001
Primary effusion lymphoma (PEL) in HIV-negative patients--a distinct clinical entity
A Klepfish, R Sarid, M Shtalrid, et al.
Leukemia & Lymphoma
|
April 12, 2003
Successful treatment of aggressive HIV-associated non-Hodgkin's lymphoma with combination chemotherapy, biotherapy with rituximab and HAART: presentation of a therapeutic option
A Klepfish, A Schattner, L Shvidel, et al.
Page
of 3